Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Stress and Nicotine Withdrawal
NCT07001930Phase 1Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Aug 2025
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cannabidiol in nicotine dependence and stress (2 arms), sponsored by Johns Hopkins University. Primary endpoints: Negative Affect as assessed by the Subjective State Scale at 220 minutes, Positive Affect as assessed by the Subjective State Scale at 220 minutes and 6 more. Started Aug 2025; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
nicotine dependencestress
Beyond the preview
Go deeper on NCT07001930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07001930.